Hcw Biologics INC S-1 registration statements

HCW Biologics Inc. has filed an amendment to its S-1 registration statement, primarily as an exhibits-only filing, detailing various corporate agreements and plans.

HCW Biologics Inc. has filed an S-1 registration statement for the resale of up to 5,693,950 shares of its common stock by selling stockholders.

HCW Biologics Inc. files an S-1/A to raise up to $5.6 million through a public offering of common stock or pre-funded warrants, while addressing ongoing Nasdaq listing compliance issues.

HCW Biologics Inc. has filed a registration statement for a $5.6 million offering of common stock and pre-funded warrants to fund clinical development and general corporate purposes.

HCW Biologics Inc. is offering up to 7.69 million units, each comprising common stock or pre-funded warrants and common stock warrants, aiming to raise $5 million to fund clinical development and address Nasdaq listing compliance.

HCW Biologics Inc. filed an exhibits-only amendment to its S-1 registration statement for a proposed public offering of up to $10 million in common stock and pre-funded warrants.

HCW Biologics Inc. is offering up to $10 million in common stock and pre-funded warrants to fund its clinical development and operations, while navigating significant financial losses and ongoing legal and regulatory challenges.

HCW Biologics Inc. filed an S-1 registration statement for the resale of up to 3.4 million common shares by selling stockholders, signaling potential dilution and highlighting ongoing financial and regulatory challenges.

HCW Biologics Inc. has filed an amendment to its Form S-1 registration statement with the SEC for a proposed offering of up to $5,000,000 in units consisting of common stock or pre-funded warrants and common stock purchase warrants.

HCW Biologics is launching a unit offering, potentially raising $5 million, to support its preclinical and clinical programs, including trials for HCW9302.

HCW Biologics has filed a registration statement for the resale of up to $40 million in shares of common stock, including shares issuable under an equity line of credit with Square Gate Capital and shares issuable upon exercise of warrants held by Armistice Capital.